EMP3 (epithelial membrane protein 3)

Show full item record

Files in this item

PDF 11-2014-EMP3ID44238ch19q13.pdf 271.8Kb

Pour citer ce document :
URI: http://hdl.handle.net/2042/62497  |   DOI : https://doi.org/10.4267/2042/62497
Title: EMP3 (epithelial membrane protein 3)
Author: Mellai, Marta; Schiffer, Davide
Abstract: Epithelial membrane protein 3 (EMP3) has recently been proposed as a candidate tumor suppressor gene (TSG) for some kinds of solid tumors. EMP3 down-regulation has been explained by its epigenetic silencing through aberrant hypermethylation of the promoter region. EMP3 repression in cancer seems to be an organ-specific phenomenon, common in neuroblastoma and gliomas, relatively common in breast cancer, and rare in esophageal squamous cell carcinoma (ESCC). Among cancer-derived cell lines, it prevails in neuroblastoma, breast cancer and ESCC whereas it is rare in glioma, non-small cell lung carcnoma (NSCLC), gastric and colon cancer-derived cell lines. EMP3 expression level is associated with clinical prognosis in neuoblastoma, ESCC, NSCLC and upper urinary tract urothelial carcinoma. In contrast, EMP3 expression may be a novel marker of tumor aggressiveness in breast cancer whereas in gliomas, EMP3 represssion by aberrant hypermethylation has a prognostic signifcance. In both tumor types, however, alternative mechanisms to the EMP3 epigenetic silencing may exist to explain EMP3 down-regulation. Moreover, EMP3 may be involved in the prostate cancer suscpetibility.
Subject: Epithelial membrane protein 3 (EMP3); tumor suppressor gene; solid tumors; promoter hypermethylation; prognosis; Genes Section
Publisher: Jean-Loup Huret (Editor-in-Chief)
Date: 2015

This item appears in the following Collection(s)

Show full item record

Advanced Search